Recon Strategy
Contact

Insights

Fifteen+ years of
Healthcare thinking.

Several hundred perspectives on the questions facing payers, providers, biopharma, medtech, and digital health — plus our running read on the clinical literature. Start with our sharpest work, or filter to your world.

Sector
All
NEJM opinion

Incentivizing even small progress in Alzheimer’s therapy should be a priority

  • Biopharma , 
  • Institutional
Working paper: Over the coming decades, Alzheimer’s disease threatens …

Read more